{"id":1501,"date":"2019-05-14T20:24:06","date_gmt":"2019-05-14T23:24:06","guid":{"rendered":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/?p=1501"},"modified":"2019-05-14T20:26:31","modified_gmt":"2019-05-14T23:26:31","slug":"fda-aprova-ramucirumabe-para-carcinoma-hepatocelular","status":"publish","type":"post","link":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/","title":{"rendered":"FDA aprova Ramucirumabe para Carcinoma Hepatocelular"},"content":{"rendered":"<section class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h2><strong>FDA aprova Ramucirumabe para Carcinoma Hepatocelular<\/strong><\/h2>\n<p>[\/vc_column_text][vc_column_text]<a href=\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-1506\" src=\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado-300x300.jpg\" alt=\"\" width=\"300\" height=\"300\" srcset=\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado-300x300.jpg 300w, http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado-150x150.jpg 150w, http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado-768x768.jpg 768w, http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado-1024x1024.jpg 1024w, http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado-560x560.jpg 560w, http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado.jpg 1080w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a>No dia 10 de maio, a ag\u00eancia reguladora dos EUA, Food and Drug Administration (FDA) aprovou o <b>Ramucirumabe<\/b> (Cyramza) como agente \u00fanico para o <b>carcinoma hepatocelular<\/b> em pacientes que t\u00eam um n\u00edvel de alfa-fetoprote\u00edna (AFP) maior ou igual \u2265 a 400 ng\/mL e foram previamente tratados com <b>sorafenibe<\/b>.<\/p>\n<p>Estudo REACH-2<\/p>\n<p>A aprova\u00e7\u00e3o foi baseada no estudo <b>REACH-2<\/b>, um estudo multic\u00eantrico, randomizado, duplo-cego, controlado com placebo, multic\u00eantrico<span class=\"Apple-converted-space\">\u00a0 <\/span>em 292 pacientes com <b>carcinoma hepatocelular<\/b> avan\u00e7ado com n\u00edveis de AFP \u2265 400 ng\/mL que tiveram progress\u00e3o da doen\u00e7a em ou ap\u00f3s o sorafenibe ou que foram intolerantes ao tratamento com sorafenib. Os pacientes foram aleatoriamente designados 2:1 para receber <b>ramucirumabe<\/b> a 8 mg\/kg, mais os melhores cuidados de suporte ou placebo, al\u00e9m do melhor tratamento de suporte a cada 2 semanas em infus\u00e3o intravenosa at\u00e9 progress\u00e3o da doen\u00e7a ou toxicidade inaceit\u00e1vel.<\/p>\n<p>O estudo mostrou aumento na sobrevida global (per\u00edodo\u00a0durante o qual um paciente permanece vivo ap\u00f3s o diagn\u00f3stico da doen\u00e7a ou\u00a0in\u00edcio do tratamento) para os pacientes que receberam <b>Ramucirumabe<\/b> comparado ao placebo.<\/p>\n<p>As rea\u00e7\u00f5es adversas mais frequentes observadas em pacientes com <b>carcinoma hepatocelular<\/b> que receberam <b>Ramucirumabe<\/b> como agente \u00fanico (\u2265 15% e \u2265 2% maior do que o placebo) foram fadiga, edema perif\u00e9rico, hipertens\u00e3o, dor abdominal, diminui\u00e7\u00e3o do apetite, protein\u00faria, n\u00e1useas e ascite. As anormalidades laboratoriais mais comuns (\u2265 30% e uma incid\u00eancia \u2265 2% maior do que o placebo) foram hipoalbuminemia, hiponatremia e trombocitopenia (diminuicao das plaquetas) .<\/p>\n<p>A dose recomendada de <b>Ramucirumabe<\/b> \u00e9 de 8 mg\/kg administrada por via intravenosa a cada 2 semanas.<\/p>\n<p><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125477s029lbl.pdf\">A FDA liberou, tamb\u00e9m, as informa\u00e7\u00f5es completas sobre a prescri\u00e7\u00e3o do Ramucirumabe (em ingl\u00eas).<\/a><\/p>\n<p>*Com informa\u00e7\u00f5es de ASCO Post[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] FDA aprova Ramucirumabe para Carcinoma Hepatocelular [\/vc_column_text][vc_column_text]No dia 10 de maio, a ag\u00eancia reguladora dos EUA, Food and Drug Administration (FDA) aprovou o Ramucirumabe (Cyramza) como agente \u00fanico para o carcinoma hepatocelular em pacientes que t\u00eam um n\u00edvel de alfa-fetoprote\u00edna (AFP) maior ou igual \u2265 a 400 ng\/mL e foram previamente tratados com sorafenibe. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1506,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_jetpack_memberships_contains_paid_content":false},"categories":[15],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA aprova Ramucirumabe para Carcinoma Hepatocelular<\/title>\n<meta name=\"description\" content=\"No dia 10 de maio, a ag\u00eancia reguladora dos EUA, Food and Drug Administration (FDA) aprovou o Ramucirumabe\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA aprova Ramucirumabe para Carcinoma Hepatocelular\" \/>\n<meta property=\"og:description\" content=\"No dia 10 de maio, a ag\u00eancia reguladora dos EUA, Food and Drug Administration (FDA) aprovou o Ramucirumabe\" \/>\n<meta property=\"og:url\" content=\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/\" \/>\n<meta property=\"og:site_name\" content=\"Ana Carolina Nobre\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DraAnaCarolinaNobre\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-14T23:24:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-05-14T23:26:31+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ana Carolina Nobre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@draananobre\" \/>\n<meta name=\"twitter:site\" content=\"@draananobre\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana Carolina Nobre\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/\",\"url\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/\",\"name\":\"FDA aprova Ramucirumabe para Carcinoma Hepatocelular\",\"isPartOf\":{\"@id\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#website\"},\"datePublished\":\"2019-05-14T23:24:06+00:00\",\"dateModified\":\"2019-05-14T23:26:31+00:00\",\"author\":{\"@id\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#\/schema\/person\/a4d56540c8859a186538d5d85f9fce42\"},\"description\":\"No dia 10 de maio, a ag\u00eancia reguladora dos EUA, Food and Drug Administration (FDA) aprovou o Ramucirumabe\",\"breadcrumb\":{\"@id\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA aprova Ramucirumabe para Carcinoma Hepatocelular\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#website\",\"url\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/\",\"name\":\"Ana Carolina Nobre\",\"description\":\"Oncologia Cl\u00ednica\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#\/schema\/person\/a4d56540c8859a186538d5d85f9fce42\",\"name\":\"Ana Carolina Nobre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/1.gravatar.com\/avatar\/1970535e274ce7bd880b47a9f7b0d1ec?s=96&d=mm&r=g\",\"contentUrl\":\"http:\/\/1.gravatar.com\/avatar\/1970535e274ce7bd880b47a9f7b0d1ec?s=96&d=mm&r=g\",\"caption\":\"Ana Carolina Nobre\"},\"url\":\"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/author\/ana\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA aprova Ramucirumabe para Carcinoma Hepatocelular","description":"No dia 10 de maio, a ag\u00eancia reguladora dos EUA, Food and Drug Administration (FDA) aprovou o Ramucirumabe","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/","og_locale":"pt_BR","og_type":"article","og_title":"FDA aprova Ramucirumabe para Carcinoma Hepatocelular","og_description":"No dia 10 de maio, a ag\u00eancia reguladora dos EUA, Food and Drug Administration (FDA) aprovou o Ramucirumabe","og_url":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/","og_site_name":"Ana Carolina Nobre","article_publisher":"https:\/\/www.facebook.com\/DraAnaCarolinaNobre","article_published_time":"2019-05-14T23:24:06+00:00","article_modified_time":"2019-05-14T23:26:31+00:00","og_image":[{"width":1080,"height":1080,"url":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado.jpg","type":"image\/jpeg"}],"author":"Ana Carolina Nobre","twitter_card":"summary_large_image","twitter_creator":"@draananobre","twitter_site":"@draananobre","twitter_misc":{"Escrito por":"Ana Carolina Nobre","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/","url":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/","name":"FDA aprova Ramucirumabe para Carcinoma Hepatocelular","isPartOf":{"@id":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#website"},"datePublished":"2019-05-14T23:24:06+00:00","dateModified":"2019-05-14T23:26:31+00:00","author":{"@id":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#\/schema\/person\/a4d56540c8859a186538d5d85f9fce42"},"description":"No dia 10 de maio, a ag\u00eancia reguladora dos EUA, Food and Drug Administration (FDA) aprovou o Ramucirumabe","breadcrumb":{"@id":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/fda-aprova-ramucirumabe-para-carcinoma-hepatocelular\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/"},{"@type":"ListItem","position":2,"name":"FDA aprova Ramucirumabe para Carcinoma Hepatocelular"}]},{"@type":"WebSite","@id":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#website","url":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/","name":"Ana Carolina Nobre","description":"Oncologia Cl\u00ednica","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#\/schema\/person\/a4d56540c8859a186538d5d85f9fce42","name":"Ana Carolina Nobre","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/#\/schema\/person\/image\/","url":"http:\/\/1.gravatar.com\/avatar\/1970535e274ce7bd880b47a9f7b0d1ec?s=96&d=mm&r=g","contentUrl":"http:\/\/1.gravatar.com\/avatar\/1970535e274ce7bd880b47a9f7b0d1ec?s=96&d=mm&r=g","caption":"Ana Carolina Nobre"},"url":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/author\/ana\/"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-content\/uploads\/2019\/05\/cancer-de-figado.jpg","_links":{"self":[{"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/posts\/1501"}],"collection":[{"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/comments?post=1501"}],"version-history":[{"count":3,"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/posts\/1501\/revisions"}],"predecessor-version":[{"id":1509,"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/posts\/1501\/revisions\/1509"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/media\/1506"}],"wp:attachment":[{"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/media?parent=1501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/categories?post=1501"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/anacarolinanobre.com.br\/blog-oncologia\/wp-json\/wp\/v2\/tags?post=1501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}